Evidence map›Paper›PMID 35787256›Full record

ArticleBMC medical imaging2022

Automated brain volumetric measures with AccuBrain: version comparison in accuracy, reproducibility and application for diagnosis.

Lei Zhao, Yishan Luo, Vincent Mok, Lin Shi

Open access · goldAbstract read
In one paragraph

Article in BMC medical imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Plasma proteomics of cerebrovascular disease, cognitive decline, and clinical outcomes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Visit-to-visit blood pressure variability, brain MRI measures, and cognition in non-demented older adults.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. A deep-learning retinal aging biomarker for cognitive decline and incident dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  8. Plasma proteomics for cognitive decline and dementia-A Southeast Asian cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lei ZhaoBrainNow Research Institute, Shenzhen, Guangdong Province, China.
Yishan LuoBrainNow Research Institute, Shenzhen, Guangdong Province, China.
Vincent MokDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
Lin ShiBrainNow Research Institute, Shenzhen, Guangdong Province, China. shilin@cuhk.edu.hk.
Chinese University of Hong Kong · CN

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

backgroundAutomated brain volumetry has been widely used to assess brain volumetric changes that may indicate clinical states and progression. Among the tools that implement automated brain volumetry, AccuBrain has been validated for its accuracy, reliability and clinical applications for the older version (IV1.2). Here, we aim to investigate the performance of an updated version (IV2.0) of AccuBrain for future use from several aspects.

methodsPublic datasets with 3D T1-weighted scans were included for version comparisons, each with Alzheimer's disease (AD) patients and normal control (NC) subjects that were matched in age and gender. For the comparisons of the brain volumetric measures quantified from the same scans, we investigated the difference of hippocampal segmentation accuracy (using Dice similarity coefficient [DSC] as the major measurement). As AccuBrain generates a composite index (AD resemblance atrophy index, AD-RAI) that indicates similarity with AD-like brain atrophy pattern, we also compared the two versions for the diagnostic accuracy of AD versus NC with AD-RAI. Also, we examined the intra-scanner reproducibility of the two versions for the scans acquired with short-intervals using intraclass correlation coefficient.

resultsAccuBrain IV2.0 presented significantly higher accuracy of hippocampal segmentation (DSC: 0.91 vs. 0.89, p < 0.001) and diagnostic accuracy of AD (AUC: 0.977 vs. 0.921, p < 0.001) than IV1.2. The results of intra-scanner reproducibility did not favor one version over the other.

conclusionsAccuBrain IV2.0 presented better segmentation accuracy and diagnostic accuracy of AD, and similar intra-scanner reproducibility compared with IV1.2. Both versions should be feasible for use due to the small magnitude of differences.

Indexed as

Alzheimer DiseaseMagnetic Resonance ImagingAtrophyBrainHumansReproducibility of ResultsAccuBrainAccuracyAutomated brain volumetryReproducibilityVersion comparison

Identifiers

PMID35787256
PMCPMC9252062
OpenAlexW4283821499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.